MR Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation

  • STATUS
    Recruiting
  • End date
    Dec 23, 2021
  • participants needed
    120
  • sponsor
    Oregon Health and Science University
Updated on 23 January 2021
vascular surgery
iron
stroke

Summary

The purpose of this study is to address safety and efficiency of a new iron particle contrast agent, ferumoxytol. This product may be more useful in viewing the vessels of the brain and areas in the brain on magnetic resonance imaging (MRI), or magnetic resonance angiography (MRA), than the standard substance, gadolinium, injected during MRI and MRA.

Other ways in which ferumoxytol may help include the following:

  1. Ferumoxytol may provide the ability to better see inflammatory lesions on magnetic resonance imaging (MRI) scans
  2. Ferumoxytol may be useful in its ability to cross blood vessels into inflammatory processes, and
  3. Ferumoxytol, because of its size and ability to get into the area next to your inflammatory lesion and could assist in the treatment of inflammatory lesions association with cardiac surgery or CNS vascular surgery.

Description

Subjects are recruited as patients in one of the neurology, neurosurgery, neuro-oncology, Multiple Sclerosis Clinic or cardiothoracic surgery clinics at OHSU. Eligible subjects will be enrolled in different groups based on their disease (MS, cardiac surgery or CNS vascular surgery, stroke). Subsequently a MRI and MRA of the brain using the standard contrast agent (Gadolinium) will be obtained; this study will be compared with the ferumoxytol-contrasted MRA and MRIs performed the next day(s).

Visit 1: the subjects are enrolled and distributed in their corresponding group; also basic laboratory studies are obtained as well as a Gadolinium contrasted MRI and MRA of the brain.

For Groups 1 and 2 (MS and Stroke):

Visit 2: Ferumoxytol will be injected as an i.v. bolus. The total dose over 2 hours will not exceed 510mg, and can be divided into multiple smaller doses such as 1 mg Fe/kg to optimize MRA imaging and may be diluted up to 4 fold in normal saline to reduce T2* effects in the MR angiography.

Visit 3: 24 hours after the second visit an MRI with the standard contrast agent will be done.

Last visit: 1 month after Ferumoxytol administration, the subject will be reassessed with physical and laboratory exams.

For Groups 3 and 4 (Cardiac surgery or CNS vascular surgery):

After the screening visit (Visit 1) and baseline MRI and MRA you will be randomly assigned to one of two groups. These groups are very similar but there are slight differences in the schedule of events.

  • Group 3a and 4a: ferumoxytol infusion (Visit 2) before surgery
  • Group 3b and 4b: ferumoxytol infusion (Visit 2) after surgery

Visit 2: Ferumoxytol will be injected as an i.v. bolus. The total dose over 2 hours will not exceed 510mg, and can be divided into multiple smaller doses such as 1 mg Fe/kg to optimize MRA imaging and may be diluted up to 4 fold in normal saline to reduce T2* effects in the MR angiography.

Visit 3: 24-72 hours after the second visit an MRI with the standard contrast agent will be done.

Last visit: 1 month after Ferumoxytol administration, the subject will be reassessed with physical and laboratory exams.

Details
Condition nervous system disorder, Diagnostic Imaging, Neurologic Disorders, neurological disorders, neurological disorder, neurologic disorder, disorders of the nervous system, nervous system disease, neurological disease, nervous system disorders, medical imaging, imaging procedure
Treatment Ferumoxytol
Clinical Study IdentifierNCT00659776
SponsorOregon Health and Science University
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Subjects must have a clinical, radiological or established histological diagnosis of multiple sclerosis, stroke, or be requiring cardiac or CNS vascular surgery. Subjects with a CNS inflammatory lesion that is suspicious for neoplasm or radiation induced inflammation (vasculitis) will also be included (group 1a). McDonald's criteria will be used for the diagnosis of multiple sclerosis
Subjects must be 18 years or older
Subjects will be followed for at least 1 month after the infusion of ferumoxytol
All subjects or their authorized representative must sign a written informed consent and give HIPAA authorization in accordance with institutional guidelines
Female subjects of child-bearing potential must be postmenopausal, surgically sterile, or using a reliable form of contraception for at least a month. These criteria can be waved at the discretion of the investigator if the one-month wait required is not in the best interest of the patient
Karnofsky must be 30% or greater

Exclusion Criteria

Subjects with clinically significant signs of uncal herniation
Subjects who have a contraindication for MRI: metal in their bodies (a cardiac pacemaker or other incompatible device), are severely agitated, or have an allergy to Gd contrast material
Subjects with known allergic or hypersensitivity reactions to parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations
Subjects with known hepatic insufficiency or cirrhosis
Subjects with known or suspected iron overload
HIV-positive subjects on combination anti-retroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
Pregnant or lactating women are excluded from this study because of possible risk to the fetus or infant
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note